Andrew Dudum Sells 128,127 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CEO Andrew Dudum sold 128,127 shares of Hims & Hers Health stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $58.40, for a total value of $7,482,616.80. Following the sale, the chief executive officer now directly owns 89,311 shares of the company's stock, valued at approximately $5,215,762.40. This represents a 58.93% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Andrew Dudum also recently made the following trade(s):

• On Friday, May 16th, Andrew Dudum sold 47,534 shares of Hims & Hers Health stock. The stock was sold at an average price of $58.25, for a total value of $2,768,855.50.
• On Tuesday, April 29th, Andrew Dudum sold 50,000 shares of Hims & Hers Health stock. The stock was sold at an average price of $36.39, for a total transaction of $1,819,500.00.
• On Wednesday, April 16th, Andrew Dudum sold 36,460 shares of Hims & Hers Health stock. The shares were sold at an average price of $28.04, for a total value of $1,022,338.40.
• On Monday, March 17th, Andrew Dudum sold 128,127 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.98, for a total value of $4,353,755.46.
• On Tuesday, February 18th, Andrew Dudum sold 128,127 shares of Hims & Hers Health stock. The stock was sold at an average price of $58.27, for a total transaction of $7,465,960.29.

Hims & Hers Health Stock Down 3.6%

NYSE HIMS traded down $2.30 on Monday, hitting $62.35. 35,635,695 shares of the stock were exchanged, compared to its average volume of 19,463,903. Hims & Hers Health, Inc. has a fifty-two week low of $13.47 and a fifty-two week high of $72.98. The company has a 50-day moving average price of $35.44 and a 200-day moving average price of $33.90. The company has a market cap of $13.96 billion, a PE ratio of 141.71 and a beta of 1.84.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported $0.20 EPS for the quarter, beating analysts' consensus estimates of $0.12 by $0.08. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $586.01 million for the quarter, compared to the consensus estimate of $535.21 million. During the same quarter in the prior year, the business posted $0.05 EPS. The business's revenue for the quarter was up 110.7% on a year-over-year basis. As a group, equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Institutional Investors Weigh In On Hims & Hers Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HIMS. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Hims & Hers Health by 23.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company's stock valued at $12,373,000 after purchasing an additional 78,543 shares during the period. Arete Wealth Advisors LLC acquired a new stake in shares of Hims & Hers Health in the 1st quarter valued at approximately $300,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Hims & Hers Health by 3.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 211,480 shares of the company's stock worth $6,249,000 after purchasing an additional 6,876 shares in the last quarter. Bosun Asset Management LLC purchased a new position in shares of Hims & Hers Health in the first quarter valued at $272,000. Finally, Alliancebernstein L.P. raised its stake in shares of Hims & Hers Health by 10.7% during the 1st quarter. Alliancebernstein L.P. now owns 812,123 shares of the company's stock worth $23,998,000 after buying an additional 78,756 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company's stock.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Canaccord Genuity Group boosted their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. Piper Sandler reissued a "neutral" rating and issued a $39.00 price target (up from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Leerink Partners lifted their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a report on Tuesday, February 25th. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Finally, TD Cowen cut Hims & Hers Health from a "buy" rating to a "hold" rating and dropped their price objective for the company from $44.00 to $30.00 in a research note on Tuesday, April 29th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $37.67.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.